Shares in Scotland-based software developer Craneware nose-dived more than 30%, or 170p, after both Investec and Brewin Dolphin downgraded the firm from buy to hold.
The brokers' decisions came despite a 12% increase in first half year revenue from $16.6m. The results include, for the first time, a full six month contribution from Craneware InSight.
MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
"A significant factor to this is the cessation of a contract administered through a third party, resulting from that third party losing its contract with the end hospital network," the firm said. "The company is currently in discussions with the new administering agents of the hospital network to replace these contracts. However, this has negatively impacted group adjusted EBITDA by approximately $0.7m during the period and is currently subject to legal review by Craneware as it examines its options to enforce its contractual rights and remedies."
Sales cycles have extended, the firm added, which the firm attributes to an unexpectedly high percentage of healthcare providers choosing to focus on achieving the 31 December 2011 deadline for the first Electronic Health Records Incentive Payments.
The share price fell fell 32.63% to 170.5p by 16:37.
NR
-
London claims victory in the Brexit warsOpinion JPMorgan Chase's decision to build a new headquarters in London is a huge vote of confidence and a sign that the City will remain Europe's key financial hub
-
The reinvention of the high street – and how to investThe high street brands that can make shopping and leisure an enjoyable experience will thrive, says Maryam Cockar
